The COVID-19 pandemic has created a rise in demand for contract services.

Meeting Increased Demand During COVID-19

Contract fill/finish services gear up for pandemic vaccine demands.

The Race to Fill and Finish

The road to approval for cell and gene therapies is paved with technical and manufacturing challenges.

On the Road to Commercialization

Topic

Articles

Following a recent expansion at its Cambridge, MA, facility, the company now houses a new suite of cellular analysis platforms that enhance its exploratory capabilities into oncology, neuroscience, and rare diseases.

Sai Life Sciences’ Screening Capabilities Enhanced with Expanded Cellular Analysis Platforms

The company’s new CytoML Experiment Suite fully automates each stage of the flow cytometry data lifecycle, allowing for clearer data visualization and analysis.

Aigenpulse’s Data Analysis Suite Automates Flow Cytometry

The radiopharmaceutical CDMO is building a new cGMP facility in Springfield, NJ.

Evergreen Theragnostics Begins Construction of Manufacturing Facility

CMDO Piramal Pharma Solutions held a grand opening at a facility they acquired in Sellersville, PA.

Piramal Pharma Solutions Opens Oral Solid Dosage Drug Product Facility

The investment at its Madison, WI, facility will expand MilliporeSigma’s capacity for high-potent active pharmaceutical ingredient production and allow for continuous flow manufacturing of ADCs.

MilliporeSigma Invests $65 Million to Expand Antibody-Drug Conjugate Manufacturing

The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.

Catalent Invests $130 Million to Expand Gene Therapy Manufacturing Capacity

Thermo Fisher Scientific is increasing access to cry-electron microscopy with the help of contract research organizations.

Thermo Fisher and CROs Expand Access to Cryo-EM

Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.


Catalent to Manufacture Drug Substance for AstraZeneca’s COVID-19 Vaccine Candidate

CDMO Avid Bioservices will provide development and drug substance manufacturing for Oragenics’ novel COVID-19 vaccine candidate, Terra CoV-2. 

Oragenics and Avid Bioservices Collaborate on Coronavirus Vaccine

Jennifer Markarian is manufacturing editor of BioPharm International.

Experts at Hovione describe progress being made in understanding how to optimize continuous processes for oral solid-dosage drug products. 

Outsourcing